Oral Wegovy, approved by FDA on December 22, 2025, launched January 5, 2026, has brought in thousands of new GLP-1 patients.23
Truveta analyzed 8,762 patients in the first six weeks; 36.1% were new to GLP-1 medications, 21.1% switched from injectable Wegovy, and 15.8% from Eli Lilly’s Zepbound.2
Novo Nordisk CEO called the rollout 'the best launch,' with 3,100 scripts by Jan. 9 per IQVIA data.2
Clinical trials showed ~17% average weight loss if all patients stayed on treatment (~14% regardless), outperforming placebo.3
Eli Lilly views this as market expansion, with their orforglipron under FDA review.2
Sources:
2. https://www.biospace.com/business/oral-wegovy-brings-in-thousands-of-new-glp-1-patients
3. https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html